The development of molecularly targeted anticancer therapies: an Eli Lilly and Company perspective.

Abstract

The ability to identify activated pathways that drive the growth and progression of cancer and to develop specific and potent inhibitors of key proteins in these pathways promises to dramatically change the treatment of cancer: A patient's cancer could be characterized at the molecular level and the information used to select the best treatment options. The development of successful therapies not only requires extensive target validation, but also new approaches to evaluating drug efficacy in animal models and in the clinic compared to the development of traditional cytotoxic agents. This article highlights Eli Lilly and Company's approach to developing targeted therapies, from target identification and validation through evaluation in the clinic. A selection of drugs in the Lilly Oncology pipeline is also discussed.

• Authors: William L Perry 3rd, Aaron Weitzman
• Journal: Clinical advances in hematology & oncology : H&O (Clin Adv Hematol Oncol) Vol. 3 Issue 3 Pg. 199-202, 237-8 (Mar 2005) ISSN: 1543-0790 [Print] United States
• PMID: 16166991 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents
• Neoplasm Proteins

Topics

• Animals
• Antineoplastic Agents (adverse effects, classification, pharmacology, therapeutic use)
• Clinical Trials as Topic
• Drug Delivery Systems
• Drug Design
• Drug Evaluation
• Drug Industry
• Drug Screening Assays, Antitumor
• Forecasting
• Humans
• Mice
• Neoplasm Proteins (antagonists & inhibitors)
• Neoplasms (drug therapy)